Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK ) properties following a single dose of ABBV-277 in healthy adult participants.
Protocol Amendment History 1 change
critical Trial completed 2026-07-09
Trial Details
NCT Number NCT07136103
Lead Sponsor AbbVie
Conditions Healthy Volunteers
Enrollment 32 participants
Start Date 2025-08-19
Primary Completion 2026-06-11 (estimated)
Study Completion 2026-06-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-08